SP
Therapeutic Areas
Genesis Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pan-mutant PIK3CA inhibitor | Oncology (e.g., breast, colorectal cancers) | Pre-clinical |
| Novel approach to tumor/host interactions | Oncology | Pre-clinical |
| Cell-death promoter | Oncology | Discovery |
| First-in-class autoimmune disorder target | Autoimmune disease | Pre-clinical |
| Validated immunology target program | Autoimmune disorders | Discovery |